Therapy of low‐risk subsets of childhood acute lymphoblastic leukemia: When do we say enough?
- 8 July 2005
- journal article
- research article
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 45 (7), 876-880
- https://doi.org/10.1002/pbc.20501
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Acute Lymphoblastic LeukemiaNew England Journal of Medicine, 2004
- Determination of minimal residual disease in leukaemia patientsBritish Journal of Haematology, 2003
- Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer GroupBlood, 2003
- Minimal residual disease in leukaemia patientsThe Lancet Oncology, 2001
- Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983–1995Leukemia, 2000
- Comparison of bone marrow transplant and chemotherapy for relapsed childhood acute lymphoblastic leukaemia: the MRC UKALL X experienceBritish Journal of Haematology, 1998
- Therapy Results in Five ALL-BFM Studies Since 1970: Implications of Risk Factors for PrognosisPublished by Springer Nature ,1987
- The impact of induction anthracycline on long‐term failure‐free survival in childhood acute lymphoblastic leukemiaMedical and Pediatric Oncology, 1986
- Five-Year Follow-Up of "Total Therapy" of Childhood Lymphocytic LeukemiaPublished by American Medical Association (AMA) ,1971
- Temporary Remissions in Acute Leukemia in Children Produced by Folic Acid Antagonist, 4-Aminopteroyl-Glutamic Acid (Aminopterin)New England Journal of Medicine, 1948